ID   Vero C1008
AC   CVCL_0574
SY   VERO C1008; VeroC1008; VEROC1008; VERO C 1008; VERO C1008 (E6); Vero 76 clone E6; Vero 76 clone E-6; Vero E-6; Vero E6; VERO E6; Vero-E6; VeroE6
DR   BTO; BTO:0004755
DR   CLO; CLO_0009527
DR   MCCL; MCC:0000479
DR   CLDB; cl4656
DR   CLDB; cl4657
DR   ATCC; CRL-1586
DR   BCRC; 60476
DR   BCRJ; 0407
DR   BioGRID_ORCS_Cell_line; 1349
DR   CCRID; 1101MON-PUMC000388
DR   CCRID; 1102MON-NIFDC00097
DR   CCRID; 3101MONGNO17
DR   CCRID; 4201MON-CCTCC00146
DR   CCTCC; GDC0146
DR   ChEMBL-Cells; CHEMBL4295411
DR   ChEMBL-Targets; CHEMBL4303840
DR   CLS; 305008
DR   ECACC; 85020206
DR   GEO; GSM758827
DR   GEO; GSM758828
DR   GEO; GSM758829
DR   GEO; GSM758830
DR   GEO; GSM758831
DR   GEO; GSM758832
DR   GEO; GSM758833
DR   GEO; GSM758834
DR   GEO; GSM758835
DR   GEO; GSM758836
DR   GEO; GSM758837
DR   GEO; GSM758838
DR   GEO; GSM758839
DR   GEO; GSM758840
DR   GEO; GSM758841
DR   GEO; GSM758842
DR   GEO; GSM758843
DR   GEO; GSM758844
DR   IZSLER; BS CL 87
DR   PRIDE; PXD018594
DR   PRIDE; PXD018760
DR   PRIDE; PXD019645
DR   PRIDE; PXD023538
DR   PubChem_Cell_line; CVCL_0574
DR   Ubigene; YC-A003
DR   Wikidata; Q54993044
RX   CelloPub=CLPUB00328;
RX   PubMed=15731278;
RX   PubMed=16494729;
RX   PubMed=19016439;
RX   PubMed=32020029;
RX   PubMed=32511316;
RX   PubMed=33389257;
RX   PubMed=34339474;
WW   https://en.wikipedia.org/wiki/Vero_cell
WW   https://en.vircell.com/products/vero-e6-cell-line/
CC   Group: Non-human primate cell line.
CC   Group: Vaccine production cell line.
CC   Virology: Susceptible to infection by many viruses. Supports the growth of slowly replicating viruses (ATCC=CRL-1586).
CC   Virology: Susceptible to infection by SARS coronavirus (SARS-CoV). Produces a lytic infection (PubMed=15731278; PubMed=16494729).
CC   Virology: Susceptible to infection by SARS coronavirus 2 (SARS-CoV-2) (COVID-19) (PubMed=32020029; PubMed=32511316; PubMed=33389257; PubMed=34339474).
CC   Doubling time: 22 hours (ATCC=CRL-1586).
CC   Derived from site: In situ; Kidney, epithelium; UBERON=UBERON_0004819.
CC   Cell type: Epithelial cell of kidney; CL=CL_0002518.
OX   NCBI_TaxID=60711; ! Chlorocebus sabaeus (Green monkey)
HI   CVCL_0603 ! Vero 76
SX   Female
AG   Adult
CA   Spontaneously immortalized cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 28
//
RX   CelloPub=CLPUB00328;
RA   Earley E.M., Johnson K.M.;
RT   "The lineage of Vero, Vero 76 and its clone C1008 in the United
RT   States.";
RL   (In) Vero cells: origin, properties and biomedical applications; Simizu B., Terasima T. (eds.); pp.26-29; Department of Microbiology School of Medicine Chiba University; Chiba (1988).
//
RX   PubMed=15731278; DOI=10.1128/JVI.79.6.3846-3850.2005;
RA   Mossel E.C., Huang C., Narayanan K., Makino S., Tesh R.B.,
RA   Peters C.J.;
RT   "Exogenous ACE2 expression allows refractory cell lines to support
RT   severe acute respiratory syndrome coronavirus replication.";
RL   J. Virol. 79:3846-3850(2005).
//
RX   PubMed=16494729; DOI=10.3201/eid1201.050496;
RA   Kaye M., Druce J., Tran T., Kostecki R., Chibo D., Morris J.,
RA   Catton M., Birch C.;
RT   "SARS-associated coronavirus replication in cell lines.";
RL   Emerg. Infect. Dis. 12:128-133(2006).
//
RX   PubMed=19016439; DOI=10.1002/9780471729259.mca04es11;
RA   Ammerman N.C., Beier-Sexton M., Azad A.F.;
RT   "Growth and maintenance of Vero cell lines.";
RL   Curr. Protoc. Microbiol. 11:A.4E.1-A.4E.7(2008).
//
RX   PubMed=32020029; DOI=10.1038/s41422-020-0282-0;
RA   Wang M.-L., Cao R.-Y., Zhang L.-K., Yang X.-L., Liu J., Xu M.-Y.,
RA   Shi Z.-L., Hu Z.-H., Zhong W., Xiao G.-F.;
RT   "Remdesivir and chloroquine effectively inhibit the recently emerged
RT   novel coronavirus (2019-nCoV) in vitro.";
RL   Cell Res. 30:269-271(2020).
//
RX   PubMed=32511316; DOI=10.1101/2020.03.02.972935;
RA   Harcourt J.L., Tamin A., Lu X.-Y., Kamili S., Kumar-Sakthivel S.,
RA   Murray J., Queen K., Tao Y., Paden C.R., Zhang J., Li Y., Uehara A.,
RA   Wang H.-B., Goldsmith C., Bullock H.A., Wang L.-J., Whitaker B.,
RA   Lynch B., Gautam R., Schindewolf C., Lokugamage K.G., Scharton D.,
RA   Plante J.A., Mirchandani D., Widen S.G., Narayanan K., Makino S.,
RA   Ksiazek T.G., Plante K.S., Weaver S.C., Lindstrom S., Tong S.-X.,
RA   Menachery V.D., Thornburg N.J.;
RT   "Isolation and characterization of SARS-CoV-2 from the first US
RT   COVID-19 patient.";
RL   bioRxiv 2020:972935-972935(2020).
//
RX   PubMed=33389257; DOI=10.1007/s10096-020-04106-0;
RA   Wurtz N., Penant G., Jardot P., Duclos N., La Scola B.;
RT   "Culture of SARS-CoV-2 in a panel of laboratory cell lines,
RT   permissivity, and differences in growth profile.";
RL   Eur. J. Clin. Microbiol. Infect. Dis. 40:477-484(2021).
//
RX   PubMed=34339474; DOI=10.1371/journal.pone.0255622;
RA   Pommerenke C., Rand U., Uphoff C.C., Nagel S., Zaborski M., Hauer V.,
RA   Kaufmann M., Meyer C., Denkmann S.A., Riese P., Eschke K., Kim Y.,
RA   Safranko Z.M., Kurolt I.-C., Markotic A., Cicin-Sain L., Steenpass L.;
RT   "Identification of cell lines CL-14, CL-40 and CAL-51 as suitable
RT   models for SARS-CoV-2 infection studies.";
RL   PLoS ONE 16:E0255622-E0255622(2021).
//